Review



caption a7 organism dalbavancin mic mbc  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC caption a7 organism dalbavancin mic mbc
    In vitro activity of <t> dalbavancin </t> against S. pneumoniae and S. aureus strains
    Caption A7 Organism Dalbavancin Mic Mbc, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caption+a7+organism+dalbavancin+mic+mbc/Trichophyton+rubrum+(Castellani)+Sabouraud/pmc01855559-326-18-43
    Average 94 stars, based on 10 article reviews
    caption a7 organism dalbavancin mic mbc - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿ "

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    Journal:

    doi: 10.1128/AAC.01264-06

    In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains
    Figure Legend Snippet: In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques Used: In Vitro, Activity Assay

    Serum PKs of dalbavancin in neutropenic infected mice following the administration of six twofold escalating doses ranging from 2.5 to 80 mg/kg intraperitoneally. Each datum point represents the mean and standard deviation for three mice. t1/2, half-life.
    Figure Legend Snippet: Serum PKs of dalbavancin in neutropenic infected mice following the administration of six twofold escalating doses ranging from 2.5 to 80 mg/kg intraperitoneally. Each datum point represents the mean and standard deviation for three mice. t1/2, half-life.

    Techniques Used: Infection, Standard Deviation

    Impacts of serum, serum ultrafiltrate, and albumin on in vitro activity of dalbavancin against selected S. aureus strains
    Figure Legend Snippet: Impacts of serum, serum ultrafiltrate, and albumin on in vitro activity of dalbavancin against selected S. aureus strains

    Techniques Used: In Vitro, Activity Assay

    Impacts of single doses of dalbavancin on organism burden in thighs of neutropenic mice infected with either S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel). Mice received either no drug or one of five twofold-increasing dose levels of dalbavancin administered via the intraperitoneal route. The microbiologic burden was determined by plate counts of thigh homogenates at selected time points over 96 h. Each symbol represents a different dose level. Each datum point represents the mean and standard deviation for four thighs.
    Figure Legend Snippet: Impacts of single doses of dalbavancin on organism burden in thighs of neutropenic mice infected with either S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel). Mice received either no drug or one of five twofold-increasing dose levels of dalbavancin administered via the intraperitoneal route. The microbiologic burden was determined by plate counts of thigh homogenates at selected time points over 96 h. Each symbol represents a different dose level. Each datum point represents the mean and standard deviation for four thighs.

    Techniques Used: Infection, Standard Deviation

    Impact of dalbavancin dosing interval on the in vivo efficacy of dalbavancin against S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel) in neutropenic mice. Five total dose levels were fractionated over a 144-h study period. Each symbol represents one of four dosing intervals. Each datum point represents the mean and standard deviation log10 CFU/thigh for four thighs.
    Figure Legend Snippet: Impact of dalbavancin dosing interval on the in vivo efficacy of dalbavancin against S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel) in neutropenic mice. Five total dose levels were fractionated over a 144-h study period. Each symbol represents one of four dosing intervals. Each datum point represents the mean and standard deviation log10 CFU/thigh for four thighs.

    Techniques Used: In Vivo, Standard Deviation

    Impact of dalbavancin dosing interval on efficacy against S. pneumoniae and S. aureus
    Figure Legend Snippet: Impact of dalbavancin dosing interval on efficacy against S. pneumoniae and S. aureus

    Techniques Used:

    Relationship between the free-drug 24-h AUC/MIC, Cmax/MIC, and T > MIC and the efficacy of dalbavancin against S. pneumoniae ATCC 10813 (top panel) and S. aureus ATCC 29213 (bottom panel) in the thighs of neutropenic mice over a 144-h treatment period. Each symbol represents the mean log10 CFU/thigh values for four thighs.
    Figure Legend Snippet: Relationship between the free-drug 24-h AUC/MIC, Cmax/MIC, and T > MIC and the efficacy of dalbavancin against S. pneumoniae ATCC 10813 (top panel) and S. aureus ATCC 29213 (bottom panel) in the thighs of neutropenic mice over a 144-h treatment period. Each symbol represents the mean log10 CFU/thigh values for four thighs.

    Techniques Used:

    Efficacy of dalbavancin against S. pneumoniae and S. aureus
    Figure Legend Snippet: Efficacy of dalbavancin against S. pneumoniae and S. aureus

    Techniques Used:

    Impact of neutrophils on in vivo efficacy of dalbavancin against S. pneumoniae
    Figure Legend Snippet: Impact of neutrophils on in vivo efficacy of dalbavancin against S. pneumoniae

    Techniques Used: In Vivo

    Dose-response relationship for dalbavancin in the neutropenic murine thigh and lung infection models against S. pneumoniae ATCC 10813 over a 6-day treatment period. Each datum point represents the mean and standard deviation for either two mice (four thighs [triangles]) or three mice (lungs [circles]).
    Figure Legend Snippet: Dose-response relationship for dalbavancin in the neutropenic murine thigh and lung infection models against S. pneumoniae ATCC 10813 over a 6-day treatment period. Each datum point represents the mean and standard deviation for either two mice (four thighs [triangles]) or three mice (lungs [circles]).

    Techniques Used: Infection, Standard Deviation

    Related Articles

    In Vitro:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin
    Article Snippet: .. Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains ..

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin
    Article Snippet: .. Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains PKs. .. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains PKs.

    Activity Assay:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin
    Article Snippet: .. Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains ..

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin
    Article Snippet: .. Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains PKs. .. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains PKs.



    Similar Products

    caption a7 organism dalbavancin mic mbc  (ATCC)
    94
    ATCC caption a7 organism dalbavancin mic mbc
    In vitro activity of <t> dalbavancin </t> against S. pneumoniae and S. aureus strains
    Caption A7 Organism Dalbavancin Mic Mbc, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/caption+a7+organism+dalbavancin+mic+mbc/Trichophyton+rubrum+(Castellani)+Sabouraud/pmc01855559-326-18-43
    Average 94 stars, based on 1 article reviews
    caption a7 organism dalbavancin mic mbc - by Bioz Stars, 2026-11
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: In Vitro, Activity Assay

    Serum PKs of dalbavancin in neutropenic infected mice following the administration of six twofold escalating doses ranging from 2.5 to 80 mg/kg intraperitoneally. Each datum point represents the mean and standard deviation for three mice. t1/2, half-life.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Serum PKs of dalbavancin in neutropenic infected mice following the administration of six twofold escalating doses ranging from 2.5 to 80 mg/kg intraperitoneally. Each datum point represents the mean and standard deviation for three mice. t1/2, half-life.

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: Infection, Standard Deviation

    Impacts of serum, serum ultrafiltrate, and albumin on in vitro activity of dalbavancin against selected S. aureus strains

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Impacts of serum, serum ultrafiltrate, and albumin on in vitro activity of dalbavancin against selected S. aureus strains

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: In Vitro, Activity Assay

    Impacts of single doses of dalbavancin on organism burden in thighs of neutropenic mice infected with either S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel). Mice received either no drug or one of five twofold-increasing dose levels of dalbavancin administered via the intraperitoneal route. The microbiologic burden was determined by plate counts of thigh homogenates at selected time points over 96 h. Each symbol represents a different dose level. Each datum point represents the mean and standard deviation for four thighs.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Impacts of single doses of dalbavancin on organism burden in thighs of neutropenic mice infected with either S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel). Mice received either no drug or one of five twofold-increasing dose levels of dalbavancin administered via the intraperitoneal route. The microbiologic burden was determined by plate counts of thigh homogenates at selected time points over 96 h. Each symbol represents a different dose level. Each datum point represents the mean and standard deviation for four thighs.

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: Infection, Standard Deviation

    Impact of dalbavancin dosing interval on the in vivo efficacy of dalbavancin against S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel) in neutropenic mice. Five total dose levels were fractionated over a 144-h study period. Each symbol represents one of four dosing intervals. Each datum point represents the mean and standard deviation log10 CFU/thigh for four thighs.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Impact of dalbavancin dosing interval on the in vivo efficacy of dalbavancin against S. pneumoniae ATCC 10813 (left panel) or S. aureus ATCC 29213 (right panel) in neutropenic mice. Five total dose levels were fractionated over a 144-h study period. Each symbol represents one of four dosing intervals. Each datum point represents the mean and standard deviation log10 CFU/thigh for four thighs.

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: In Vivo, Standard Deviation

    Impact of dalbavancin dosing interval on efficacy against S. pneumoniae and S. aureus

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Impact of dalbavancin dosing interval on efficacy against S. pneumoniae and S. aureus

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques:

    Relationship between the free-drug 24-h AUC/MIC, Cmax/MIC, and T > MIC and the efficacy of dalbavancin against S. pneumoniae ATCC 10813 (top panel) and S. aureus ATCC 29213 (bottom panel) in the thighs of neutropenic mice over a 144-h treatment period. Each symbol represents the mean log10 CFU/thigh values for four thighs.

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Relationship between the free-drug 24-h AUC/MIC, Cmax/MIC, and T > MIC and the efficacy of dalbavancin against S. pneumoniae ATCC 10813 (top panel) and S. aureus ATCC 29213 (bottom panel) in the thighs of neutropenic mice over a 144-h treatment period. Each symbol represents the mean log10 CFU/thigh values for four thighs.

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques:

    Efficacy of dalbavancin against S. pneumoniae and S. aureus

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Efficacy of dalbavancin against S. pneumoniae and S. aureus

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques:

    Impact of neutrophils on in vivo efficacy of dalbavancin against S. pneumoniae

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Impact of neutrophils on in vivo efficacy of dalbavancin against S. pneumoniae

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: In Vivo

    Dose-response relationship for dalbavancin in the neutropenic murine thigh and lung infection models against S. pneumoniae ATCC 10813 over a 6-day treatment period. Each datum point represents the mean and standard deviation for either two mice (four thighs [triangles]) or three mice (lungs [circles]).

    Journal:

    Article Title: In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin ▿

    doi: 10.1128/AAC.01264-06

    Figure Lengend Snippet: Dose-response relationship for dalbavancin in the neutropenic murine thigh and lung infection models against S. pneumoniae ATCC 10813 over a 6-day treatment period. Each datum point represents the mean and standard deviation for either two mice (four thighs [triangles]) or three mice (lungs [circles]).

    Article Snippet: Beta-lactam resistance did not affect the in vitro potency of dalbavancin. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Organism Dalbavancin MIC/MBC (mg/liter) MIC (mg/liter) Penicillin Methicillin S. pneumoniae strain 1199 0.004/0.004 1.0 1293 0.004/0.004 2.0 1325 0.008/0.008 2.0 1329 0.008/0.008 2.0 ATCC 10813 0.03/0.03 0.008 S. aureus strain ATCC 25923 0.12/0.50 0.12 33591 0.12/0.25 >8.0 31005 0.06/0.12 0.12 MRSA 0.06/0.25 >8.0 Smith 0.06/0.25 0.12 307109 0.06/0.12 >8.0 Open in a separate window In vitro activity of dalbavancin against S. pneumoniae and S. aureus strains

    Techniques: Infection, Standard Deviation